Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07797478
PHASE1

A Study of RO7890597 in Healthy Adult Volunteers

Sponsor: Genentech, Inc.

View on ClinicalTrials.gov

Summary

This study will evaluate the safety, pharmacokinetics (PK), and activity of single and multiple doses of RO7890597 compared with placebo in healthy volunteers. The study includes single ascending dose (SAD) stage, multiple ascending dose (MAD) stage, food-effect and proton pump inhibitor (PPI) stages, and a supplemental drug-drug interaction (DDI) stage.

Official title: A Phase I Study to Evaluate the Safety and Pharmacokinetics of RO7890597 Following Single and Multiple Ascending Doses, and the Effects of Food, Proton-Pump Inhibition, And CYP3A Inhibition in Healthy Adult Volunteers

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

139

Start Date

2026-08-28

Completion Date

2027-06-08

Last Updated

2026-09-01

Healthy Volunteers

Yes

Interventions

DRUG

RO7890597

Participants will receive RO7890597 as per the schedule described in the protocol.

DRUG

Placebo

Participants will receive matching placebo as per the schedule described in the protocol.

DRUG

Rabeprazole

Participants will receive rabeprazole as per the schedule described in the protocol.

DRUG

Itraconazole

Participants will receive itraconazole as per the schedule described in the protocol.

Locations (1)

ICON (LPRA) - Lenexa

Lenexa, Kansas, United States